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Somatostatinomas are rare neuroendocrine tumours usually lo‐
cated in the pancreas or in the periampullary region of the duode‐
num, rarely in the jejunum, the ovaries or elsewhere. Patients with 
somatostatinomas most often present with nonspecific symptoms 
such as abdominal pain or weight loss. A more specific clinical man‐
ifestation is the somatostatinoma syndrome characterized by dia‐
betes, cholelithiasis and steatorrhoea.1 Moreover, hypoglycaemia 
has been associated with somatostatin‐secreting neuroendocrine 
tumours.2‐4 The pathogenesis of hypoglycaemia in patients with so‐
matostatinoma has not been well characterized. We describe two 
patients with malignant somatostatinomas who presented with hy‐
poglycaemia. In both patients, the pattern of hypoglycaemia was 
well characterized and documented at a functional and morpholog‐
ical level.
Patient 1, a 76‐year‐old man, presented at his local hospital with 
hypoglycaemic episodes occurring exclusively in the late postprandial 
period, often preceded by a short episode of diarrhoea following car‐
bohydrate‐rich meals. On abdominal CT, he was found to have mul‐
tiple liver tumour masses, and he was then referred to our clinic for 
further investigations. Fasting plasma glucose was 7.7 mmol/L. No 
hypoglycaemic symptoms occurred during a 72‐hour fast (plasma glu‐
cose concentration 4.8 mmol/L at the end of the fast). In contrast, 
venous plasma glucose concentration dropped to 1.5 mmol/L and 
the patient developed severe neuroglycopenic symptoms 240 min‐
utes after intake of 75 g glucose during an oral glucose tolerance test 
(oGTT). Insulin concentrations during the oGTT showed an exces‐
sive increase from 44 pmol/L at baseline up to 6998 pmol/L within 
120 minutes following the oral glucose challenge. An intravenous GTT, 
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Abstract
Introduction: Somatostatin‐secreting neuroendocrine tumours may present with di‐
abetes, cholelithiasis and steatorrhoea. In addition, hypoglycaemia has been associ‐
ated with somatostatinomas. However, the mechanism of hypoglycaemia in patients 
with somatostatinomas has not been well characterized.
Methods: We describe two patients with recurrent neuroglycopenic episodes caused 
by somatostatin‐secreting neuroendocrine tumours in the liver, detected by abdomi‐
nal CTs and whole‐body octreotide scintigraphy scans and confirmed by biopsy.
Results: Pancreatic islet hyperplasia and co‐secretion of insulin (in addition to soma‐
tostatin) from tumour cells, respectively, have been characterized as completely dis‐
tinct mechanisms of hypoglycaemia at both the functional and morphological levels 
in these two patients.
Conclusions: Hypoglycaemia may be caused by different mechanisms in patients 
with somatostatinomas.
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however, did not provoke hypoglycaemia. A tumour‐produced incretin 
could not be identified (we checked for GLP‐1, CCK, pro CCK and GIP), 
but somatostatin levels were markedly increased in the basal state 
(5 nmol/L, normal <0.1) and decreased during the glucose challenge. 
Selective arterial calcium stimulation with hepatic venous sampling 
(ASVS) was performed, and insulin concentrations were measured as 
previously described.5 ASVS demonstrated increased insulin secretion 
in response to calcium injection into all arteries supplying the pancreas 
but not in response to calcium injection into the proper hepatic artery 
supplying the tumour (Figure 1). Biopsy of the liver tumour was per‐
formed, and histological examination revealed a neuroendocrine tu‐
mour. A diagnosis of a somatostatin‐secreting neuroendocrine tumour 
with postprandial hypoglycaemia, mild diabetes mellitus and cholecys‐
tolithiasis was made.
Because the patient declined resection of the right hepatic lobe, 
transarterial tumour embolization was performed. Postprandial hy‐
poglycaemia improved following the procedure. However, within 
three years, the neuroendocrine tumour progressed and the pa‐
tient died at the age of 79 years. Post‐mortem analysis revealed a 
malignant somatostatinoma with disseminated tumour infiltrates 
forming nodules up to 10 mm in the pancreas and prominent liver 
metastasis. The primary localization of the somatostatinoma in the 
pancreas was not detected until autopsy. In addition to the soma‐
tostatinoma, histological examination of the pancreas revealed islet 
hyperplasia throughout the pancreas. Most strikingly, the number 
F I G U R E  1   Selective arterial calcium stimulation (ASVS) tests. 
ASVS was performed as previously described (5). Insulin (and 
somatostatin for patient 2) levels in the left hepatic vein are shown 
as a multiple of basal 30, 60 and 120 s after the intraarterial injection 
of calcium (0.025 mEq Ca++ per kg body weight) into arteries 
supplying the pancreas and the liver (shown in the sequence of 
injections): in the first patient, the superior mesenteric artery (SMA), 
the splenic artery (SA), the proper hepatic artery and the (inferior) 
gastroduodenal artery (GDA); in the second patient, the SA, the 
SMA, right hepatic artery, the GDA and the left hepatic artery (LHA). 
A more than twofold rise in the insulin level in the hepatic vein 
indicates pathological β‐cells in the arterial distribution of the artery 
stimulated. In patient 1, the pathological increase in insulin levels in 
the hepatic vein after calcium stimulation of all pancreatic arteries 
is suggestive for islet cell hyperplasia. In patient 2, the pathological 
increase in insulin levels following calcium injection into the LHA 
indicates an insulin‐secreting tumour in the left hepatic lobe
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F I G U R E  2   Indium‐111 octreotide scintigraphy. Indium‐111 
octreotide scintigraphy of patient 2 revealing increased activity in 
left hepatic lobe (arrow)
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of islets of Langerhans was increased, and their size and shape were 
very variable with individual hypertrophic islets. Islet hyperplasia as 
cause of hypoglycaemia in this patient was well characterized at the 
functional (ASVS test) and morphological level.
Patient 2, a 56‐year‐old woman, presented with recurrent hy‐
poglycaemic episodes. Neuroglycopenic symptoms developed in 
an erratic manner but preferentially while fasting. In a local hos‐
pital, an HbA1c of 4.0%, random low blood glucose readings and 
a liver tumour by an abdominal CT scan were found. She was sent 
to us for further investigations and treatment. During a super‐
vised fast, plasma glucose concentration dropped to 1.1 mmol/L 
after 21 hours. Insulin concentration at the time of hypoglycaemia 
(458 pmol/L) confirmed hyperinsulinaemic hypoglycaemia. The ab‐
dominal CT scan showed a large liver tumour (10 cm in diameter) 
in the left hepatic lobe. An octreotide scan of the liver tumour was 
positive (Figure 2). A biopsy of the liver tumour was performed, 
and histological examination revealed a neuroendocrine tumour 
positive for synaptophysin and chromogranin A. The differential 
diagnosis included islet carcinoma of the pancreas metastatic to 
liver that could not be detected. However, the ASVS test demon‐
strated a normal insulin secretion response to calcium injection 
into all arteries supplying the pancreas but a markedly increased 
(more than 10‐fold) insulin secretion following calcium injection 
into the left hepatic artery. Moreover, calcium stimulated the se‐
cretion of somatostatin by the liver tumour (more than 13‐fold) 
but not from the pancreas (Figure 1). Resection of the liver tumour 
was performed. Immunohistochemically, tumour cells stained 
markedly positive for somatostatin (95%) and insulin (5%); inter‐
estingly, staining for the two hormones was restricted to distinct 
cell populations and not uniform throughout the tumour (Figure 3). 
Following resection of the liver tumour, insulin fell rapidly whereas 
plasma glucose levels increased, initially overshooting to an in‐
creased level and soon returning into a normal range. The patient 
remained free of hypoglycaemia and diabetes for the rest of her 
life. However, manifestations of tumour disease recurred after 
3 years, and repeated imaging then revealed progressive hepatic 
but no pancreatic tumour masses. The patient died 6 years after 
surgery (at the age of 62 years). Her family members declined a 
post‐mortem analysis. Evidence for somatostatin secretion by liver 
tumours is very rare, and usually, somatostatin‐positive neuroen‐
docrine tumours are derived from the pancreas and the duodenum. 
Co‐secretion of insulin (in addition to somatostatin) by the hepatic 
somatostatinoma was well characterized as mechanism of hypo‐
glycaemia in this patient.
In conclusion, pancreatic islet cell hyperplasia and co‐secretion 
of insulin (in addition to somatostatin) from tumour cells, respec‐
tively, have been characterized as completely distinct mechanisms 
of hypoglycaemia at the functional and morphological level in these 
two patients with malignant somatostatinomas.
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F I G U R E  3   Pathology findings. H&E 
staining 5× (A) of the liver metastasis, 
showing a trabecular and nesting growth 
pattern. Immunohistochemistry for 
insulin shows a distinct cell population 
(B 10 × magnification), 10×, compared to 
immunohistochemistry of somatostatin 
(C, 10 × magnification). The two cell 
populations are intermingled, but without 
different aspect in cell morphology
(A)
(B) (C)
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